Silychristin, a flavonolignan derived from the milk thistle, is a potent inhibitor of the thyroid hormone transporter MCT8

Endocrinology

Volumn 157, Issue 4, 2016, Pages 1694-1701

  Johannes, Jörg ^b   Jayarama Naidu, Roopa ^a   Meyer, Franziska ^a   Wirth, Eva Katrin ^a   Schweizer, Ulrich ^b   Schomburg, Lutz ^a   Köhrle, Josef ^a   Renko, Kostja ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIOTHYRONINE; MONOCARBOXYLATE TRANSPORTER 8; PROTEIN INHIBITOR; SILICRISTIN; SILYMARIN; THYROID HORMONE RECEPTOR; CARRIER PROTEIN; PLANT EXTRACT; SLC16A2 PROTEIN, MOUSE; THYROID HORMONE;

ANIMAL CELL; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DRUG IDENTIFICATION; HORMONE INHIBITION; IC50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SILYBUM MARIANUM; SUBSTRATE CONCENTRATION; UPTAKE ASSAY; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DOG; DOSE RESPONSE; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MDCK CELL LINE; METABOLISM; NEWBORN; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; MADIN DARBY CANINE KIDNEY CELLS; MALE; MEMBRANE TRANSPORT PROTEINS; MICE, KNOCKOUT; MILK THISTLE; PLANT EXTRACTS; SILYMARIN; THYROID HORMONES; TRIIODOTHYRONINE;

EID: 84964490344     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1933     Document Type: Article

References (31)

1. Visser WE, Friesema EC, Jansen J, Visser TJ. Thyroid hormone transport in and out of cells. Trends Endocrinol Metab. 2008;19: 50-56.
2. Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem. 2003;278:40128-40135.
3. Kinne A, Kleinau G, Hoefig CS, et al. Essential molecular determinants for thyroid hormone transport and first structural implications for monocarboxylate transporter 8. J Biol Chem. 2010;285: 28054-28063.
4. Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet. 2004;364:1435-1437.
5. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet. 2004;74:168-175.
6. Illouz F, Braun D, Briet C, Schweizer U, Rodien P. Endocrine sideeffects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014;171:R91-R99.
7. Braun D, Kim TD, le Coutre P, Köhrle J, Hershman JM, Schweizer U. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab. 2012;97: E100-E105.
8. Jayarama-Naidu R, Johannes J, Meyer F, et al. A nonradioactive uptake assay for rapid analysis of thyroid hormone transporter function. Endocrinology. 2015;156:2739-2745.
9. Hofmann PJ, Schomburg L, Köhrle J. Interference of endocrine disrupters with thyroid hormone receptor-dependent transactivation. Toxicol Sci. 2009;110:125-137.
10. Köhrle J. Environment and endocrinology: the case of thyroidology. Ann Endocrinol. 2008;69:116-122.
11. Murk AJ, Rijntjes E, Blaauboer BJ, et al. Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol In Vitro. 2013;27:1320-1346.
12. Braun D, Lelios I, Krause G, Schweizer U. Histidines in potential substrate recognition sites affect thyroid hormone transport by monocarboxylate transporter 8 (MCT8). Endocrinology. 2013; 154:2553-2561.
13. Groeneweg S, Lima de Souza EC, Visser WE, Peeters RP, Visser TJ. Importance of His192 in the human thyroid hormone transporter MCT8 for substrate recognition. Endocrinology. 2013;154:2525-2532.
14. Saller R, Melzer J, Reichling J, Brignoli R, Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komplement. 2007;14:70-80.
15. Freitag AF, Cardia GF, da Rocha BA, et al. Hepatoprotective effect of silymarin (Silybum marianum) on hepatotoxicity induced by acetaminophen in spontaneously hypertensive rats. Evid Based Complement Alternat Med. 2015;2015:538317.
16. Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan SC. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fund Clin Pharmacol. 2009;23:735-745.
17. Toklu HZ, Tunali Akbay T, Velioglu-Ogunc A, et al. Silymarin, the antioxidant component of Silybum marianum, prevents sepsis-induced acute lung and brain injury. J Surg Res. 2008;145:214-222.
18. Ashkavand Z, Malekinejad H, Amniattalab A, Rezaei-Golmisheh A, Vishwanath BS. Silymarin potentiates the anti-inflammatory effects of Celecoxib on chemically induced osteoarthritis in rats. Phytomedicine. 2012;19:1200-1205.
19. Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol. 2007; 224:350-359.
20. El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009; 16:391-400.
21. Renko K, Schache S, Hoefig CS, et al. An improved nonradioactive screening method identifies genistein and xanthohumol as potent inhibitors of iodothyronine deiodinases. Thyroid. 2015;25(8):962-968.
22. Roth S, Kinne A, Schweizer U. The tricyclic antidepressant desipramine inhibits T3 import into primary neurons. Neurosci Lett. 2010;478:5-8.
23. Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH, Visser TJ. Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol. 2008; 22:1357-1369.
24. Braun D, Kinne A, Brauer AU, et al. Developmental and cell typespecific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia. 2011;59:463-471.
25. Kleinau G, Schweizer U, Kinne A, et al. Insights into molecular properties of the human monocarboxylate transporter 8 by combining functional with structural information. Thyroid Res. 2011; 4(suppl 1):S4.
26. Schweizer U, Johannes J, Bayer D, Braun D. Structure and function of thyroid hormone plasma membrane transporters. Eur Thyroid J. 2014;3:143-153.
27. Kock K, Xie Y, Hawke RL, Oberlies NH, Brouwer KL. Interaction of silymarin flavonolignans with organic anion-transporting polypeptides. Drug Metab Dispos. 2013;41:958-965.
28. Friesema EC, Jansen J, Milici C, Visser TJ. Thyroid hormone transporters. Vitamins Horm. 2005;70:137-167.
29. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos. 2008;36:65-72.
30. Galhardi F, Mesquita K, Monserrat JM, Barros DM. Effect of silymarin on biochemical parameters of oxidative stress in aged and young rat brain. Food Chem Toxicol. 2009;47:2655-2660.
31. Nencini C, Giorgi G, Micheli L. Protective effect of silymarin on oxidative stress in rat brain. 2007;14:129-135.